

0001/PTO Rev. 10/95		U.S. Department of Commerce Patent and Trademark Office		Application Number	10/660,434
				Filing Date	September 10, 2003
				First Named Inventor	Guennadi V. Glinski
				Group Art Unit Number	Not yet known
				Examiner Name	Not yet known
Total Number of Pages in This Submission		7*	Attorney Docket Number		23543-07570

TRANSMITTAL FORM

*to be used for all correspondence during pendency of
filed application)*

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Check Enclosed <input checked="" type="checkbox"/> Return Receipt Postcard <input type="checkbox"/> Response to Notice to File Missing Parts <input type="checkbox"/> Assignment & Recordation Cover Sheet <input type="checkbox"/> Declaration <input type="checkbox"/> Power of Attorney <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Information Disclosure Statement & PTO/SB/08A <input checked="" type="checkbox"/> Copies of IDS Cited References <input type="checkbox"/> Request for Corrected Filing Receipt <input type="checkbox"/> Request for Correction of Recorded Assignment <input type="checkbox"/> Amendment/Response: [] Page(s) <input type="checkbox"/> After Final <input type="checkbox"/> Status Request <input type="checkbox"/> Revocation and Substitute Power of Attorney	<input type="checkbox"/> Issue Fee Transmittal <input type="checkbox"/> Letter to Chief Draftsperson <input type="checkbox"/> Formal Drawing(s): [] Sheet(s) of Figure(s) [] <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i> <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
--	--

REMARKS: *Page count does not include cited references.

SIGNATURE OF ATTORNEY OR AGENT


Signature:	<i>Susan T. Hubl</i>		
Attorney/Reg. No.:	Susan T. Hubl, Ph.D., Reg. No. 47,668	Dated:	Dec. 9, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence, including the enclosures identified above, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. If the Express Mail Mailing Number is filled in below, then this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service pursuant to 37 CFR 1.10.			
Signature:	<i>Susan T. Hubl</i>		
Typed or Printed Name:	Susan T. Hubl, Ph.D.	Dated:	Dec. 9, 2003
Express Mail Mailing Number (optional):			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Guennadi V. Glinskii
APPLICATION NO.: 10/660,434
FILING DATE: September 10, 2003
TITLE: Gene Segregation And Biological Sample Classification Methods
EXAMINER: Not yet known
GROUP ART UNIT: Not yet known
ATTY. DKT. NO.: 23543-07570



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below:

Dated: 12/9/03

By: Susan T. Hubl
Susan T. Hubl, Ph.D., Reg. No.: 47,668

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Under 37 CFR §§ 1.56 and 1.97-98

SIR:

Pursuant to the provisions of 37 CFR §§ 1.56 and 1.97-98, enclosed herewith is modified form PTO/SB/08A listing references for consideration by the Examiner. Enclosed is a copy of each listed reference that may be material to the examination of this application, and for which there may be a duty to disclose.

The filing of this Information Disclosure Statement shall not be construed as a representation regarding the completeness of the list of references, or that inclusion of a reference in this list is an admission that it is prior art or is pertinent to this application, or that a search has been made, or as an admission that the information listed is, or may be considered to be, material to patentability, or that no other material information exists, and shall not be construed as an admission against interest in any manner.

This Information Disclosure Statement is being filed:

- ☒ within three months of the filing date of the application, or date of entry into the national stage of an international application, or before the mailing date of a first office action on the merits, whichever event last occurred;
- ☐ before the mailing of a first official action after the filing of a request for continued examination (RCE) under 37 CFR § 1.114;

- ☐ after three months of the filing date of this national application or the date of entry of the national stage in an international application, or after the mailing date of the first official action on the merits, whichever event last occurred, but before the mailing date of the first to occur of either: (1) a final action under 37 CFR §1.113; or (2) an action that otherwise closes prosecution in the application, and:
 - ☐ attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR. § 1.97(c); OR
 - ☐ Applicant certifies pursuant to 37 CFR § 1.97(e) that:
 - ☐ each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; OR
 - ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement;
- ☐ on or before the payment of the issue fee but after the mailing date of the first to occur of either: (1) a final action under 37 CFR § 1.113; (2) a notice of allowance under 37 CFR § 1.311; or (3) an action that otherwise closes prosecution in the application, and:
 - ☐ Applicant certifies pursuant to 37 CFR. § 1.97(e) that:
 - ☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
 - ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this

PATENT


certification after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated under 37 CFR § 1.56(c) more than three months prior to the filing of this Statement; AND

- ☐ attached hereto is the fee set forth under 37 CFR §1.17(p) for submission of this Information Disclosure Statement under 37 CFR. § 1.97(c); OR
- ☐ after the payment of the issue fee. Applicant requests that the information contained in this Information Disclosure Statement be placed in the file according to 37 CFR § 1.97(i), although the information may not be considered by the USPTO.
- ☐ This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application No. APPLICATION NO., filed on DATE FILED, and the references cited therein are hereby referenced, but are not required to be provided in this application under 37 CFR § 1.98(d).
- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not received by any individual designated in 37 CFR § 1.56(c) more than thirty days prior to the filing of this Information Disclosure Statement. 37 CFR § 1.704(d).
- ☒ Applicant submits that no fee is required for the consideration of this Information Disclosure Statement.

Consideration of the listed references and favorable action are solicited.

Respectfully submitted,
GUENNADI V. GLINSKI

Dated: Dec. 9, 2003

By: 
Susan T. Hubl, Ph.D., Reg. No.: 47,668
Fenwick & West LLP
Silicon Valley Center
801 California Street
Mountain View, CA 94041
Tel.: (415) 875-2413
Fax.: (415) 395-0879

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application N .	10/660,434	
			Filing Date	September 10, 2003	
			First Named Inventor	Guennadi V. Glinski	
			Art Unit	Not yet known	
			Examiner Name	Not yet known	
Sheet	1	of	2	Attorney Docket Number	23543-07570

mailed 12/4/03

DEC 15 2003

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US-		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1	CLARK, E.A., et al., Genomic Analysis of Metastasis Reveals an Essential Role for RhoC, Nature, 2000, pp.532-535, volume 406.	
	C2	DHANASEKARAN, S.M., et al., Delineation Of Prognostic Biomarkers In Prostate Cancer, Nature, August 23, 2001, pp. 822-826, volume 412.	
	C3	FOROZAN, F., et al., Comparative Genomic Hybridization Analysis of 38 Breast Cancer Cell Lines: A Basis for Interpreting Complementary DNA Microarray Data, Cancer Research, 2000, pp. 4519-4525, volume 60.	
	C4	GLINSKY, G.V., et al., 2002 Microarray gene expression of tumor progression in the nude mouse model of human prostate cancer. In Proceedings of the 93 rd Annual Meeting of the American Association for Cancer Research, April 6-10, San Francisco, CA 43:462 (Abstract #4480).	
	C5	LUO, J., et al., Gene Expression Signature of Benign Prostatic Hyperplasia Revealed by cDNA Microarray Analysis, Prostate, 2002, pp.189-200, volume 51.	
	C6	LUO, J., et al., Human Prostate Cancer and Benign Prostatic Hyperplasia: Molecular Dissection By Gene Expression Profiling, Cancer Research, 2001, pp. 4683-4688, volume 61.	
	C7	MAGEE, J.A., et al., Expression Profiling Reveals Hepsin Overexpression In Prostate Cancer, Cancer Research, 2001, pp. 5692-5696, volume 61.	
	C8	NOTTERMAN, Daniel. A., et al., Transcriptional Gene Expression Profiles of Colorectal Adenoma, Adenocarcinoma, and Normal Tissue Examined of Oligonucleotide Arrays, Cancer Research, April 1, 2001, pp. 3124-3130, volume 61.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1395950.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application N .	10/660,434
Filing Date	September 10, 2003
First Named Inventor	Guennadi V. Glinski
Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	23543-07570

Sheet

2

of

2

DEC 15 2003

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C9	PEROU, C.M., et al., Distinctive Gene Expression Patterns in Human Mammary Epithelial Cells and Breast Cancers, Proc. Natl. Acad. Sci. USA, 1999, pp. 9212-9217, volume 96.	
	C10	PEROU, C.M., et al., Molecular Portrait of Human Breast Tumors, Nature, 2000, pp. 747-752, volume 406.	
	C11	POZACK, J.R., et al., Genome-Wide Analysis of DNA-Copy Number Changes Using cDNA Microarrays, Nature Genetics, 1999, pp. 41-46, volume 23.	
	C12	RHODES, D.R., et al., Meta-analysis of Microarrays: Interstudy Validation of Gene Expression Profiles Reveals Pathways Dysregulation in Prostate Cancer, Cancer Research, 2002, pp. 4427-4433, volume 62.	
	C13	ROSS, Douglas T., et al., Systematic Variation in Gene Expression Patterns in Human Cancer Cell Lines, Nature Genetics, March 2000, pp. 227-235, volume 24.	
	C14	SINGH, D., et al., Gene Expression Correlates of Clinical Prostate Cancer Behavior, Cancer Cell, March 2002, pp. 203-209, volume 1.	
	C15	SØRLIE, Therese, et al., Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with Clinical Implications, Proc. Natl. Acad. Sci. USA, September 11, 2001, pp. 10869-10874, volume 98, number 19.	
	C16	STAMEY, T.A., et al., Molecular Genetic Profiling Of Gleason Grade 4/5 Prostate Cancers Compared to Benign Prostatic Hyperplasia, J.Urol., December 2001, pp. 2171-2177, volume 166(6).	
	C17	SU, Andrew I., et al., Molecular Classification of Human Carcinomas by Use of Gene Expression Signatures, Cancer Research, October 15, 2001, pp. 7388-7393, volume 61.	
	C18	VAN'T Veer, Laura J., et al., Gene Expression Profiling Predicts Clinical Outcome of Breast Cancer, Nature, January 31, 2002, pp. 530-536, volume 415.	
	C19	WELSH, J.B., et al., Analysis of Gene Expression Identifies Candidate Markers and Pharmacological Targets in Prostate Cancer, Cancer Research, 2001, pp. 5974-5978, volume 61.	
	C20	WELSH, J.B., et al., Analysis of Gene Expression Profiles in Normal and Neoplastic Ovarian Tissue Samples Identifies Candidate Molecular Markers of Epithelial Ovarian Cancer, Proc. Natl. Acad. Sci. USA, January 30, 2001, pp. 1176-1181, volume 98, number 3.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

23543/07570/DOCS/1395950.1